US 12,410,221 B2
Tumor antigens for determining cancer therapy
Ugur Sahin, Mainz (DE); Claudia Paret, Mainz (DE); Kirsten Vormbrock, Mainz (DE); Christian Bender, Mainz (DE); Petra Simon, Mainz (DE); Christoph Hartmann, Frankfurt (DE); Stefanie Hubich, Mainz (DE); Thomas Bukur, Mainz (DE); and Thorsten Litzenberger, Olsbrücken (DE)
Assigned to BioNTech SE, Mainz (DE); and TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz (DE)
Filed by BioNTech SE, Mainz (DE); and TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg—Universität Mainz, Mainz (DE)
Filed on Feb. 28, 2023, as Appl. No. 18/176,283.
Application 18/176,283 is a division of application No. 16/229,841, filed on Dec. 21, 2018, granted, now 11,628,209.
Application 16/229,841 is a continuation of application No. 14/908,246, granted, now 10,188,712, issued on Jan. 29, 2019, previously published as PCT/EP2014/066328, filed on Jul. 30, 2014.
Claims priority of application No. PCT/EP2013/002271 (WO), filed on Jul. 30, 2013; and application No. PCT/EP2013/003173 (WO), filed on Oct. 22, 2013.
Prior Publication US 2023/0355732 A1, Nov. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 31/00 (2006.01); A61K 39/00 (2006.01); C07K 14/47 (2006.01); C12Q 1/6886 (2018.01); G01N 33/53 (2006.01); G01N 33/574 (2006.01)
CPC C07K 14/4748 (2013.01) [A61K 39/0011 (2013.01); A61K 39/001189 (2018.08); C12Q 1/6886 (2013.01); G01N 33/57415 (2013.01); G01N 33/57484 (2013.01); A61K 2039/507 (2013.01); A61K 2039/53 (2013.01); A61K 2039/70 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01); G01N 2333/47 (2013.01)] 13 Claims
 
1. A method for treating triple negative breast cancer in a patient having triple negative breast cancer, the method comprising:
(a) determining an expression pattern of a set of tumor antigens in a sample from the patient having triple negative breast cancer, wherein the set of tumor antigens comprises at least one selected from chromosome X open reading frame 61 (CXorf61), Preferentially expressed Antigen in Melanoma (PRAME), and cancer antigen 1 (CAGE1);
(b) diagnosing the patient having triple negative breast cancer as needing a cancer therapy regimen when at least one tumor antigen selected from CXorf61, PRAME, and CAGE1 is expressed; and
(c) treating the patient having triple negative breast cancer with an immunotherapeutic that targets the at least one tumor antigen expressed in the patient.